Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
暂无分享,去创建一个
V. Lorusso | M. de Lena | M. Lena | V. Gebbia | A. Sobrero | N. Silvestris | A. Sobrero | P. Comella | L. Manzione | G. Rosati | S. Palmeri | A. Mangiameli | G. Pezzella | E. Crucitta | S. Mancarella | D. Muci | Gebbia
[1] J. Baselga,et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine , 2002, Cancer.
[2] B. Redman,et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] I. Bodrogi,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Baselga,et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Scher,et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract , 2000, Cancer.
[6] C. Sternberg. Gemcitabine in bladder cancer. , 2000, Seminars in oncology.
[7] T. Kuzel,et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Kikuo Okamura,et al. 進行性尿路上皮腫瘍に対するM-VAC(methotrexate,vinblastine,doxorubicin and cisplatin)療法と治療強度に基づいた効果 , 1997 .
[9] P. Francis,et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. , 1996, Gynecologic oncology.
[10] M. Moore. Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review , 1996, Cancer.
[11] F. Shepherd,et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.
[12] G. Peters,et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.
[13] D. Neuberg,et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Logothetis,et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] I. Tannock,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.
[17] R. Kefford,et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Simon,et al. Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.
[19] F. Freiha,et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Fuchs Da,et al. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978 .
[21] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[22] Antonius A. Miller,et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability , 2004, Cancer Chemotherapy and Pharmacology.
[23] R. Johnson,et al. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978, Cancer treatment reports.
[24] M. Moore. Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review , 2022 .